111 Inc ADR(YI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.73 | Insider Own | 1.82% | Shs Outstand | 5.2M | Perf Week | -0.35% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | -94.39% | Shs Float | 5.1M | Perf Month | -13.77% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | - | Inst Own | 2.22% | Short Float | 0.08% | Perf Quarter | -21.21% |
| Income | -0.02B | P/S | 0.01 | EPS this Y | - | Inst Trans | 73.6% | Short Ratio | 0.31 | Perf Half Y | -52.5% |
| Sales | 1.50B | P/B | - | EPS next 5Y | - | ROA | -4.99% | Short Interest | 0.00M | Perf YTD | 11.33% |
| Book/sh | -13.02 | P/C | 0.26 | EPS past 3/5Y | 47.72% 33.28% | ROE | - | 52W High | -74.49% ($11.17) | Perf Year | -35.08% |
| Cash/sh | 10.82 | P/FCF | - | Sales past 3/5Y | -4.53% 8.01% | ROIC | - | 52W Low | 14.92% ($2.48) | Perf 3Y | -87.33% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -45.45% | Gross Margin | 5.73% | Volatility(W/M) | 6.41% 4.72% | Perf 5Y | -94.52% |
| Dividend TTM | - | EV/Sales | 0.09 | Sales Y/Y TTM | -23.9% | Oper. Margin | -0.52% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.51 | EPS Q/Q | -109.25% | Profit Margin | -1.02% | RSI (14) | 32.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.07 | Sales Q/Q | -23.76% | SMA20 | -7.11% ($3.07) | Beta | 0.76 | Target Price | $12.01 |
| Payout | - | Debt/Eq | - | Earnings | 2026/9/17 | SMA50 | -14.02% ($3.31) | Rel Volume | 1.56 | Prev Close | $2.98 |
| Employees | 1063 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -43.84% ($5.07) | Avg Volume(3M) | 0.01M | Price | $2.85 |
| IPO | 2018/9/12 | Option/Short | No/Yes | Trades | 68 | Volume | 21,640 | Change | -4.36% |
111 is a Chinese digital healthcare and pharmaceutical distribution company that operates its own B2C online pharmacy, "1 Drugstore," and a B2B pharmacy wholesale platform, "1 Drugmall." Its core strategy is to build a direct supply chain for small pharmacies and hospitals, connecting China's pharmaceutical distribution through an integrated online and offline model.
Over the past 1 year, on the lower side
74% below its 1-year high.
Traded more than usual. That is 156% of its average volume.
YI has weak earning power
Of every $100 in sales, $0.52 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1. Peers typically go for $285.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
FBND Fidelity Total Bond ETF 28.3B 
USHY iShares Broad USD High Yield Corporate Bond ETF 26.8B 
SDY State Street SPDR S&P Dividend ETF 23.8B 
HYG iShares iBoxx USD High Yield Corporate Bond ETF 17.8B 
BINC iShares Flexible Income Active ETF 16.9B It ranks #9 of 10 in the industry
Based on market cap of $15M.
FAQ
What kind of company is YI?
YI belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of YI?
The market cap of YI is approximately $15M, ranking 5,304 within its sector.
What is the 52-week high and low for YI?
YI has recorded a 52-week high of $11.17 and a low of $2.48.
